Mycobacterium chelonae infection associated with adalimumab therapy.
Díaz
F
F
Urkijo
J C
JC
Mendoza
F
F
de la Viuda
J M
JM
Blanco
M
M
Unzurrunzaga
A
A
Ayarza
R
R
D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D009165:Mycobacterium Infections, Nontuberculous / Q000139:chemically induced / Q000175:diagnosis* / Q000517:prevention & control; D016926:Mycobacterium chelonae; D009894:Opportunistic Infections / Q000139:chemically induced / Q000175:diagnosis* / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab